Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Jishnu Malgie, Mariëlle I Wilde, Pascal R D Clephas, Mireille E Emans, Stefan Koudstaal, Jeroen Schaap, Arend Mosterd, Jan van Ramshorst, Alexander J Wardeh, Sandra van Wijk, Mieke van den Heuvel, Eric Wierda, C Jan Willem Borleffs, Colette Saraber, Saskia L M A Beeres, Roland van Kimmenade, Wouter Jansen Klomp, Robert Denham, Carlos A da Fonseca, IJsbrand T Klip, Olivier C Manintveld, Robert M A van der Boon, Clara E E van Ofwegen, Ayten Yilmaz, Ron Pisters, Gerard C M Linssen, Nikola Faber, Loek van Heerebeek, Julio E C van de Swaluw, Lex J Bouhuijzen, Marco C Post, Aaf F M Kuijper, Ka Wai Wu, Eugène A van Beek, Tim Hesselink, Lennaert Kleijn, Maurice J M Kurvers, René A Tio, Jorina Langerveld, Bas M van Dalen, J W Martijn van Eck, M Louis Handoko, Walter R M Hermans, Hetty J J Koornstra-Wortel, Mariusz K Szymanski, Dennis Rooker, Kenneth Tandjung, Sabine C M Eijsbouts, Folkert W Asselbergs, Peter van der Meer, Hans-Peter Brunner-La Rocca, Rudolf A de Boer, Jasper J Brugts
AIMS: Despite clear guideline recommendations for initiating four drug classes in all patients with heart failure (HF) with reduced ejection fraction (HFrEF) and the availability of rapid titration schemes, information on real-world implementation lags behind. Closely following the 2021 ESC HF guidelines and 2023 focused update, the TITRATE-HF study started to prospectively investigate the use, sequencing, and titration of guideline-directed medical therapy (GDMT) in HF patients, including the identification of implementation barriers...
May 12, 2024: European Journal of Heart Failure
#2
JOURNAL ARTICLE
Uwe Zeymer, Robert Groves, Stephan Hupfer
BACKGROUND: Sacubitril/valsartan (Sac/Val) is the first angiotensin receptor-neprilysin inhibitor indicated for symptomatic chronic heart failure (HF) with reduced ejection fraction (HFrEF). Given most patients with HF in Germany are managed by general practitioners, AURORA-HF investigated the baseline characteristics and 1‑year follow-up of patients starting Sac/Val in primary care in Germany. METHODS: This was a prospective, multicenter, observational study, with all treatment decisions independent of participation...
April 24, 2024: Herz
#3
REVIEW
Sergio Henrique Rodolpho Ramalho, André Luiz Pereira de Albuquerque
PURPOSE OF REVIEW: Chronic obstructive pulmonary disease (COPD) is common in heart failure (HF), and it has a significant impact on the prognosis and quality of life of patients. Additionally, COPD is independently associated with lower adherence to first-line HF therapies. In this review, we outline the challenges of identifying and managing HF with preserved (HFpEF) and reduced (HFrEF) ejection fraction with coexisting COPD. RECENT FINDINGS: Spirometry is necessary for COPD diagnosis and prognosis but is underused in HF...
March 28, 2024: Current Heart Failure Reports
#4
JOURNAL ARTICLE
Mena Gewarges, Roslyn Mainland, Katherine Wilkinson, Jaime Sklar, Andrew Gentilin, Bianca McLean, Omar I Hajjaj, Mali Worme, Spencer Lalonde, Raumil Patel, Yulia Lin, Jeannie Callum, Stephanie Poon
INTRODUCTION: Iron deficiency anaemia (IDA) is common in patients with heart failure (HF) and is associated with advanced HF and increased mortality. Intravenous iron supplementation increases exercise tolerance, improves quality of life, and decreases symptoms among patients with HF with reduced ejection fraction (HFrEF) and iron deficiency. Despite this, many patients are not screened or treated for IDA. We aimed to increase rates of screening and treatment of IDA among HF patients through the introduction of curated materials to aid HF clinicians with appropriate screening and treatment...
February 23, 2024: BMJ Open Quality
#5
REVIEW
Joshua M Riley, James J Fradin, Douglas H Russ, Eric D Warner, Yevgeniy Brailovsky, Indranee Rajapreyar
Pulmonary hypertension (PH) caused by left heart disease, also known as post-capillary PH, is the most common etiology of PH. Left heart disease due to systolic dysfunction or heart failure with preserved ejection fraction, valvular heart disease, and left atrial myopathy due to atrial fibrillation are causes of post-capillary PH. Elevated left-sided filling pressures cause pulmonary venous congestion due to backward transmission of pressures and post-capillary PH. In advanced left-sided heart disease or valvular heart disease, chronic uncontrolled venous congestion may lead to remodeling of the pulmonary arterial system, causing combined pre-capillary and post-capillary PH...
January 22, 2024: Journal of Clinical Medicine
#6
JOURNAL ARTICLE
Jing-Wu Yang, Li Ma, Zhen Zhang, Ran Xiong, Qing-Yang Meng, Hui-Long Huang, Wei- Bo Zeng, Tong Bai, Zheng-Tian Wang
Heart failure (HF) can damage various organs, including the liver, a phenomenon known as "cardiohepatic syndrome." The latter is characterized by liver congestion and hepatic artery hypoperfusion, which can lead to liver damage. In this study, we aimed to assess liver damage quantitatively in chronic HF (CHF) with sound touch elastography (STE). A total of 150 subjects were enrolled, including HF with reduced ejection fraction (HFrEF) groups (left ventricular ejection fraction ≤40%, n = 45), HF with mildly reduced ejection fraction (HFmrEF) groups (left ventricular ejection fraction between 41% and 49%, n = 40), and right-sided HF (RHF) groups (n = 25); normal groups (n = 40)...
November 10, 2023: American Journal of Cardiology
#7
JOURNAL ARTICLE
Dwi Surya Supriyana, Arsita Eka Prasetyawati, Habibie Arifianto
BACKGROUND: Clinical studies have shown that electroacupuncture (EA) has therapeutic and modulatory effects on managing heart failure (HF) risk factors. OBJECTIVE: This study aimed to determine the impact of combination drugs and EA on chronic HF patients with reduced ejection fraction (HFrEF) to maintain a stable heart rate (HR) and mean arterial pressure (MAP). MATERIALS AND METHODS: This single-blind clinical randomized controlled trial included 42 patients with chronic HFrEF...
December 1, 2023: Medical Acupuncture
#8
REVIEW
Ross M Dies, Corrie N Jackson, Chelsi J Flanagan, Evan S Sinnathamby, Noah J Spillers, Pooja Potharaju, Naina Singh, Giustino Varrassi, Shahab Ahmadzadeh, Sahar Shekoohi, Alan D Kaye
Heart failure (HF) is a chronic and progressive clinical disorder characterized by an inability to pump sufficient blood to meet metabolic demands. It poses a substantial global healthcare burden, leading to high morbidity, mortality, and economic impact. Current treatments for HF include lifestyle modifications, guideline-directed medical therapies (GDMT), and device interventions, but the need for novel therapeutic approaches remains significant. The introduction of vericiguat, a soluble guanylate cyclase stimulator, has shown promise in improving outcomes for heart failure patients...
December 2023: Curēus
#9
JOURNAL ARTICLE
Jiongxing Wu, Mingxi Chen, Huan Wang, Yuyi Zhu, Yaqi Chen, Shihong Zhang, Deren Wang
Acute ischemic stroke (AIS) can be complicated by heart failure involving preserved ejection fraction (HFpEF) or reduced ejection fraction (HFrEF), and whether or not the prognosis differs between the 2 types of patients remains unclear. We compared the clinical characteristics and outcomes of the 2 types of patients at 3 months after the stroke.We retrospectively analyzed patients who, between 1 January 2018 and 1 January 2021, experienced AIS that was complicated by HFrEF or HFpEF. All patients had been prospectively registered in the Chengdu Stroke Registry...
December 27, 2023: International Heart Journal
#10
JOURNAL ARTICLE
Edimar Alcides Bocchi, Guilherme Veiga Guimarães, Cristhian Espinoza Romero, Paula Keiko Sato, Vera Lúcia Teixeira de Freitas, Edite Hatsumi Yamashiro Kanashiro, Célia Regina Furuchó, Fatima Das Dores Cruz, Érika Shimoda Nakanishi, Felipe Delatorre Busser, Rita Cristina Bezerra, Elizabeth Visone Nunes Westphalen, Mussya Cisotto Rocha, Maria Aparecida Shikanai Yasuda
BACKGROUND: Chagas disease, endemic in Latin America and spreading globally due to emigration, has a significant health burden, particularly in relation to chagasic heart failure (HF). Chagasic cardiomyopathy (CCM) is characterized by chronic inflammatory myocardial disease. This study aimed to identify inflammatory parameters and biomarkers that could aid in the management of patients with chagasic HF. METHODS AND FINDINGS: A cohort study was conducted at a tertiary cardiology single-center over a mean follow-up period of 2...
December 18, 2023: PLoS Neglected Tropical Diseases
#11
JOURNAL ARTICLE
Lauren Adamchick, Kari Kurtzhalts, Kristen Fodero, Rebecca Winski, Arthur K Chan, Kari A Mergenhagen
OBJECTIVE(S): Heart failure (HF) is chronic and progressive. Individuals with a left ventricular ejection fraction (LVEF or EF) < 40% are classified as having heart failure with reduced ejection fraction (HFrEF). Black patients have the highest incidence of HF and are more likely to suffer serious consequences from the disease. Identifying and addressing racial disparities in care is vital to ensuring health equity. The primary objective was to determine the association of race with 1-year heart HF admission rates for white and black patients, when adjusted for EF and age...
2024: Journal of the American Pharmacists Association: JAPhA
#12
JOURNAL ARTICLE
Pharmacoutilization and adherence to sacubitril/valsartan in real world: the REAL.IT study in HFrEF.
Massimo Iacoviello, Gabriele Di Gesaro, Filippo Maria Sarullo, Daniela Miani, Mauro Driussi, Michele Correale, Claudio Bilato, Andrea Passantino, Erberto Carluccio, Alessandra Villani, Luca Degli Esposti, Chiara d'Agostino, Elena Peruzzi, Simone Poli, Andrea di Lenarda
AIMS: The current European Society of Cardiology (ESC) guidelines provide clear indications for the treatment of acute and chronic heart failure (HF). Nevertheless, there is a constant need for real-world evidence regarding the effectiveness, adherence, and persistence of drug therapy. We investigated the use of sacubitril/valsartan for the treatment of HF with reduced ejection fraction in real-world clinical practice in Italy. METHODS AND RESULTS: An observational, retrospective, non-interventional cohort study based on electronic medical records from nine specialized hospital HF centres in Italy was carried out on patients with prescription of sacubitril/valsartan...
February 2024: ESC Heart Failure
#13
JOURNAL ARTICLE
Abeer Bakhsh, Alaa AlSayed, Mohammed AlTamimi, Raneem Alodhaib, Munira Binhudhud, Hadeel Ghazal, Yahya Al Hebaishi
BACKGROUND: Women have unique risk factors for heart disease and a higher risk of cardiovascular mortality. Heart failure (HF) prevalence in women is affected by age, pregnancy, and menopause. More understanding of HF etiology, management, and outcome in women is needed. METHOD: a retrospective study of women diagnosed with HF following at a heart function clinic (HFC) in a tertiary cardiac center. RESULTS: A total of 1988 HF patients were screened...
2023: American Journal of Cardiovascular Disease
#14
REVIEW
Allissa Long, Marissa Salvo
OBJECTIVE: To describe the pharmacology, clinical efficacy, and safety evidence of sotagliflozin, the first approved dual inhibitor of sodium-glucose cotransporter (SGLT) 1 and SGLT2, in heart failure (HF) management. DATA SOURCES: A literature search of studies published between January 2012 and September 2023 were identified using PubMed, MEDLINE, and clinicaltrials.gov with search terms of "sotagliflozin," "Inpefa," or "LX4211." STUDY SELECTION AND DATA EXTRACTION: All available studies in English were considered...
November 28, 2023: Annals of Pharmacotherapy
#15
REVIEW
Carlo Lavalle, Luca Di Lullo, Jean Pierre Jabbour, Marta Palombi, Sara Trivigno, Marco Valerio Mariani, Francesco Summaria, Paolo Severino, Roberto Badagliacca, Fabio Miraldi, Antonio Bellasi, Carmine Dario Vizza
Patients with an established diagnosis of heart failure (HF) with reduced ejection fraction (HFrEF) are prone to experience episodes of worsening symptoms and signs despite continued therapy, termed "worsening heart failure" (WHF). Despite guideline-directed medical therapy, worsening of chronic heart failure accounts for almost 50% of all hospital admissions for HF, and patients experiencing WHF carry a substantially higher risk of death and hospitalization than patients with "stable" HF. New drugs are emerging as arrows in the quiver for clinicians to address the residual risk of HF hospitalization and cardiovascular deaths in patients with WHF...
November 7, 2023: Journal of Clinical Medicine
#16
JOURNAL ARTICLE
Meriem Drissa, Marouan Krid, Fares Azaiez, Essia Mousli, Soumaya Yahyaoui, Cyrine Aouji, Habiba Drissa
BACKGROUND: Heart failure (HF) is a serious and frequent pathology. It represents a major public health problem. We have few data about this pathology in our country. The aim of our study is to determine the epidemiological, clinical, therapeutic, and prognostic characteristics of new-onset HF with reduced left ventricular ejection fraction (HFrEF) and to study the degree of conformity of the management of HF with international recommendations. RESULTS: Our study population includes 210 patients hospitalized for HFrEF newly diagnosed...
November 7, 2023: Egyptian Heart Journal: EHJ
#17
REVIEW
Sunanda Tah, Melissa Valderrama, Maham Afzal, Javed Iqbal, Aisha Farooq, Muhammad Ali Lak, Karol Gostomczyk, Elhama Jami, Mahendra Kumar, Akshay Sundaram, Mouhammad Sharifa, Mustafa Arain
Heart failure (HF) with preserved ejection fraction (HFpEF) is a clinical syndrome in which patients have signs and symptoms of HF due to high left ventricular (LV) filling pressure despite normal or near normal LV ejection fraction. It is more common than HF with reduced ejection fraction (HFrEF), and its diagnosis and treatment are more challenging than HFrEF. Although hypertension is the primary risk factor, coronary artery disease and other comorbidities, such as atrial fibrillation (AF), diabetes, chronic kidney disease (CKD), and obesity, also play an essential role in its formation...
September 2023: Curēus
#18
Maamannan Venkataraj, Tyler Pierotti, Manush Sondhi, Shravya Balmuri, Samina Hayat
Cardiac sarcoidosis (CS) is a rare auto-immune disorder where immune cells form granulomas in the heart that may lead to potential arrhythmias and heart failure. Due to the low prevalence of CS, the management remains challenging, requiring a multidisciplinary approach. In addition to the management of the resulting arrhythmias and heart failure, corticosteroids and immunosuppressants are used as anti-inflammatories to prevent disease progression. Immunosuppressive regimens for the treatment of CS are not yet well established...
September 2023: Curēus
#19
JOURNAL ARTICLE
Seun Osundolire, Robert J Goldberg, Kate L Lapane
BACKGROUND: Heart failure and chronic obstructive pulmonary disease (COPD) are leading cause of death throughout the world. Few recent studies have, however, examined possible sex and type of heart failure (HFpEF, HFrEF, and unspecified/other heart failure) differences in the prevalence of these chronic conditions among nursing home residents. OBJECTIVES: The aim of this study is to examine the magnitude of concomitant COPD and differences according to sex and heart failure type, in terms of the prevalence of COPD among nursing home residents with heart failure...
September 15, 2023: Clinical Respiratory Journal
#20
JOURNAL ARTICLE
Sophie Ribeiro Coelho, Arnaud Ancion, Mai-Linh Nguyen-Trung, Patrizio Lancellotti
Heart failure remains, despite increasing therapeutic advances, a major burden in terms of public health. It is associated with a significant mortality and dramatically impacts the daily life of these patients with, among other things, repeated and prolonged hospitalizations. This article aims to focus on the therapeutic modalities for the management of patients with heart failure and reduced ejection fraction (HFrEF) recommended by the European Society of Cardiology. A significant change is taking place in pharmacological treatment following the discovery of new drug classes...
September 2023: Revue Médicale de Liège
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
